Journal of the Korean Academy of Child and Adolescent Psychiatry

Korean Academy of Child and Adolescent Psychiatry (대한소아청소년정신의학회)
권호 표지
DOI QR코드

DOI QR Code

Clinical Characteristics of Methylphenidate Use in Korean Children and Adolescents with Autism Spectrum Disorder : A Retrospective Study

소아청소년 자폐 스펙트럼장애에서 메칠페니데이트 사용의 임상적 특징에 대한 후향적 분석

  • Park, Jin-Park (Department of Psychiatry, Seoul National Hospital) ;
  • Lee, Jong-Il (Department of Psychiatry, Seoul National Hospital) ;
  • Jhin, Hea-Kyung (Center for Child and Adolescent Psychiatry, LPJ Mind Health Clinic) ;
  • Min, Hae-Ji (Department of Adolescent Psychiatry, Seoul National Hospital) ;
  • Hwang, Jun-Won (Department of Psychiatry, Kangwon National University Hospital, Kangwon National University School of Medicine) ;
  • Kim, Ye-Ni (Department of Adolescent Psychiatry, Seoul National Hospital)
  • 박진박 (국립서울병원 정신건강의학과) ;
  • 이종일 (국립서울병원 정신건강의학과) ;
  • 진혜경 (LPJ 마음건강의원 소아청소년연구소) ;
  • 민혜지 (국립서울병원 청소년정신과) ;
  • 황준원 (강원대학교 의학전문대학원 강원대학교병원 정신건강의학교실) ;
  • 김예니 (국립서울병원 청소년정신과)
  • Received : 2012.06.28
  • Accepted : 2012.08.23
  • Published : 2012.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives : The purpose of this study was to investigate clinical characteristics of children and adolescents with autism spectrum disorders (ASDs) using methylphenidate (MPH). Methods : Retrospective review of the charts of 79 children and adolescents with ASDs, who visited the Department of Child and Adolescent Psychiatry of Seoul National Hospital, from July 2010 to July 2011, was conducted. Changes in illness severity and improvement were measured using the Clinical Global Impression-Severity of illness (CGI-S) and Clinical Global Impression-Improvement (CGI-I) Scales. Results : We found that MPH was prescribed in 23 (29.1%) children and adolescents. Of the 23 patients on MPH, 4 patients (17.4%) were on MPH monotherapy and 18 patients (78.3%) were using risperidone concomitantly. MPH was prescribed primarily for symptoms of hyperactivity and impulsivity in ASDs patients. The mean dosage of MPH was $26.2{\pm}11.1$mg/day and mean duration of treatment was $31.9{\pm}28.7$ months. Mean CGI-S score improved significantly from baseline to endpoint (from $5.4{\pm}0.6$ to $4.1{\pm}0.9$ ; p<.01). MPH was reported to be effective in 17 patients (17/23, 73.9%), and 10 patients (10/23, 43.5%) reported side effects. Side effects included decreased appetite (4/23, 17.4%), tic (2/23, 8.6%), sleep disturbances (2/23, 8.6%), headache (1/23, 4.3%) and irritability (1/23, 4.3%). Conclusion : The results of this study demonstrate that MPH may be used effectively and safely in children and adolescents with ASDs with hyperactivity and impulsivity. Future controlled trials are needed to confirm these findings.

Keywords

References

  1. Ha EH, Lee SJ, Oh KJ, Hong KE. Parent-adolescent agreement in the assessment of behavior problems of adolescents: comparison of factor structures of K-CBCL and YSR. J Korean Acad Child Adolesc Psychiatry 1998;9:3-12.
  2. Nazeer A, Ghaziuddin M. Autism spectrum disorders: clinical features and diagnosis. Pediatr Clin North Am 2012;59:19-25. https://doi.org/10.1016/j.pcl.2011.10.007
  3. Autism and Developmental Disabilities Monitoring Network Surveillance Year 2008 Principal Investigators; Centers for Disease Control and Prevention. Prevalence of autism spectrum disorders--Autism and Developmental Disabilities Monitoring Network, 14 sites, United States, 2008. MMWR Surveill Summ 2012;61:1-19.
  4. Kim YS, Leventhal BL, Koh YJ, Fombonne E, Laska E, Lim EC, et al. Prevalence of autism spectrum disorders in a total population sample. Am J Psychiatry 2011;168:904-912. https://doi.org/10.1176/appi.ajp.2011.10101532
  5. Hillman J. Childhood Autism. New York: Taylor & Francis Group; 2007. p.49.
  6. Virues-Ortega J. Applied behavior analytic intervention for autism in early childhood: meta-analysis, meta-regression and dose-response meta-analysis of multiple outcomes. Clin Psychol Rev 2010;30:387-399. https://doi.org/10.1016/j.cpr.2010.01.008
  7. Munshi KR, Gonzalez-Heydrich J, Augenstein T, D'Angelo EJ. Evidence-based treatment approach to autism spectrum disorders. Pediatr Ann 2011;40:569-574. https://doi.org/10.3928/00904481-20111007-08
  8. Canitano R, Scandurra V. Psychopharmacology in autism: an update. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:18-28. https://doi.org/10.1016/j.pnpbp.2010.10.015
  9. Kaplan G, McCracken JT. Psychopharmacology of autism spectrum disorders. Pediatr Clin North Am 2012;59:175-187, xii. https://doi.org/10.1016/j.pcl.2011.10.005
  10. Canitano R, Scandurra V. Risperidone in the treatment of behavioral disorders associated with autism in children and adolescents. Neu-ropsychiatr Dis Treat 2008;4:723-730.
  11. Shea S, Turgay A, Carroll A, Schulz M, Orlik H, Smith I, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 2004;114:e634-e641. https://doi.org/10.1542/peds.2003-0264-F
  12. Pandina GJ, Bossie CA, Youssef E, Zhu Y, Dunbar F. Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial. J Autism Dev Disord 2007;37:367-373. https://doi.org/10.1007/s10803-006-0234-7
  13. Curran MP. Aripiprazole: in the treatment of irritability associated with autistic disorder in pediatric patients. Paediatr Drugs 2011;13: 197-204. https://doi.org/10.2165/11207230-000000000-00000
  14. Fung LK, Chahal L, Libove RA, Bivas R, Hardan AY. A retrospective review of the effectiveness of aripiprazole in the treatment of sensory abnormalities in autism. J Child Adolesc Psychopharmacol 2012;22:245-248. https://doi.org/10.1089/cap.2010.0103
  15. Hollander E, Chaplin W, Soorya L, Wasserman S, Novotny S, Rusoff J, et al. Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. Neuropsychopharmacology 2010;35:990-998 https://doi.org/10.1038/npp.2009.202
  16. Hollander E, Phillips A, Chaplin W, Zagursky K, Novotny S, Wasserman S, et al. A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology 2005;30:582-589. https://doi.org/10.1038/sj.npp.1300627
  17. Hazell P. Drug therapy for attention-deficit/hyperactivity disorder-like symptoms in autistic disorder. J Paediatr Child Health 2007;43: 19-24. https://doi.org/10.1111/j.1440-1754.2007.00995.x
  18. Grzadzinski R, Di Martino A, Brady E, Mairena MA, O'Neale M, Petkova E, et al. Examining autistic traits in children with ADHD: does the autism spectrum extend to ADHD? J Autism Dev Disord 2011;41:1178-1191. https://doi.org/10.1007/s10803-010-1135-3
  19. Murray MJ. Attention-deficit/Hyperactivity Disorder in the context of Autism spectrum disorders. Curr Psychiatry Rep 2010;12:382-388. https://doi.org/10.1007/s11920-010-0145-3
  20. Research Units on Pediatric Psychopharmacology Autism Network. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry 2005;62:1266-1274. https://doi.org/10.1001/archpsyc.62.11.1266
  21. Ghuman JK, Aman MG, Lecavalier L, Riddle MA, Gelenberg A, Wright R, et al. Randomized, placebo-controlled, crossover study of methylphenidate for attention-deficit/hyperactivity disorder symptoms in preschoolers with developmental disorders. J Child Adolesc Psychopharmacol 2009;19:329-339. https://doi.org/10.1089/cap.2008.0137
  22. Santosh PJ, Baird G, Pityaratstian N, Tavare E, Gringras P. Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study. Child Care Health Dev 2006;32:575-583. https://doi.org/10.1111/j.1365-2214.2006.00631.x
  23. Stigler KA, Desmond LA, Posey DJ, Wiegand RE, McDougle CJ. A naturalistic retrospective analysis of psychostimulants in pervasive developmental disorders. J Child Adolesc Psychopharmacol 2004; 14:49-56. https://doi.org/10.1089/104454604773840481
  24. Nickels K, Katusic SK, Colligan RC, Weaver AL, Voigt RG, Barbaresi WJ. Stimulant medication treatment of target behaviors in children with autism: a population-based study. J Dev Behav Pediatr 2008;29:75-81. https://doi.org/10.1097/DBP.0b013e31815f24f7
  25. Cortese S, Castelnau P, Morcillo C, Roux S, Bonnet-Brilhault F. Psychostimulants for ADHD-like symptoms in individuals with autism spectrum disorders. Expert Rev Neurother 2012;12:461-473. https://doi.org/10.1586/ern.12.23

Cited by

  1. Proper administration of psychostimulants vol.61, pp.8, 2018, https://doi.org/10.5124/jkma.2018.61.8.502